Application potential of toll-like receptors in cancer immunotherapy

Medicine (United States)

Volumn 95, Issue 25, 2016, Pages

  Shi, Ming ^a   Chen, Xi ^a   Ye, Kangruo ^a   Yao, Yuanfei ^a   Li, Yu ^a  

^a HARBIN INSTITUTE OF TECHNOLOGY   (China)

Author keywords

cancer therapy; innate immunity; therapeutic target; toll like receptor

Indexed keywords

TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; HUMAN; METASTASIS; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES;

HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; NEOPLASMS; TOLL-LIKE RECEPTORS;

EID: 84976350804     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003951     Document Type: Review

References (93)

1. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511.
2. Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004;303:1522-6.
3. Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annu Rev Biochem 2007;76:141-65.
4. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16:3-9.
5. Shi M, Zhang Y, Liu L, et al. MAP1S protein regulates the phagocytosis of bacteria and Toll-like receptor (TLR) signaling. J Biol Chem 2016;291:1243-50.
6. Suga H, Sugaya M, Fujita H, et al. TLR4, rather than TLR2, regulates wound healing through TGF-beta and CCL5 expression. J Dermatol Sci 2014;73:117-24.
7. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Tolllike receptors and hyaluronan. Nat Med 2005;11:1173-9.
8. Jiang D, Liang J, Li Y, et al. The role of Toll-like receptors in noninfectious lung injury. Cell Res 2006;16:693-701.
9. Cai Z, Sanchez A, Shi Z, et al. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 2011;71:2466-75.
10. Shcheblyakov DV, Logunov DY, Tukhvatulin AI, et al. Toll-like receptors (TLRs): the role in tumor progression. Acta Naturae 2010; 2:21-9.
11. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-Tumor treatment. Cell Mol Biol Lett 2009;14:248-72.
12. Shi M, Yao Y, Han F, et al. MAP1S controls breast cancer cell TLR5 signaling pathway and promotes TLR5 signaling-based tumor suppression. PloS One 2014;9:e86839.
13. Zhao S, Zhang Y, Zhang Q, et al. Toll-like receptors and prostate cancer. Front Immunol 2014;5:352.
14. Tye H, Kennedy CL, Najdovska M, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012;22:466-78.
15. Kennedy CL, Najdovska M, Tye H, et al. Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis. Oncogene 2014;33:2540-6.
16. Jing Y, Liang H, Zhang Y, et al. Up-regulation of Toll-like receptor 9 in osteosarcoma. Anticancer Res 2015;35:5839-43.
17. Kumar MM, Adurthi S, Ramachandran S, et al. Toll-like receptors 7, 8, and 9 expression and function in primary human cervical cancer Langerhans cells: evidence of anergy. Int J Gynecol Cancer 2013;23: 184-92.
18. Wang L, Zhao Y, Qian J, et al. Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion. Cancer 2013;119:782-91.
19. Song EJ, Kang MJ, Kim YS, et al. Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med 2011; 28:115-9.
20. Tanaka J, Sugimoto K, Shiraki K, et al. Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Int J Oncol 2010;37: 805-14.
21. Akira S, Hemmi H. Recognition of pathogen-Associated molecular patterns by TLR family. Immunol Lett 2003;85:85-95.
22. Yu L, Wang L, Chen S. Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis. Cell Mol Life Sci 2012;69:935-49.
23. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009;457:102-6.
24. Chalmin F, Ladoire S, Mignot G, et al. Membrane-Associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010;120:457-71.
25. Rerole AL, Jego G, Garrido C. Hsp70: anti-Apoptotic and tumorigenic protein. Methods Mol Biol 2011;787:205-30.
26. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-45.
27. Yoon SI, Kurnasov O, Natarajan V, et al. Structural basis of TLR5-flagellin recognition and signaling. Science 2012;335:859-64.
28. George J, Motshwene PG, Wang H, et al. Two human MYD88 variants, S34Y and R98C, interfere with MyD88-IRAK4-myddosome assembly. J Biol Chem 2011;286:1341-53.
29. Bertin S, Pierrefite-Carle V. Autophagy and toll-like receptors: a new link in cancer cells. Autophagy 2008;4:1086-9.
30. Umemura N, Zhu J, Mburu YK, et al. Defective NF-kappaB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA. Cancer Res 72:45-55.
31. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
32. Mantovani A. Cancer: inflaming metastasis. Nature 2009;457:36-7.
33. Killeen SD, Wang JH, Andrews EJ, et al. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword. Br J Cancer 2006;95:247-52.
34. Huang Y, Cai B, Xu M, et al. Gene silencing of Toll-like receptor 2 inhibits proliferation of human liver cancer cells and secretion of inflammatory cytokines. PloS One 2012;7:e38890.
35. Jing YY, Han ZP, Sun K, et al. Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med 2012;10:98.
36. Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21:504-16.
37. Cheng YX, Qi XY, Huang JL, et al. Toll-like receptor 4 signaling promotes the immunosuppressive cytokine production of human cervical cancer. Eur J Gynaecol Oncol 2012;33:291-4.
38. Hsiao CC, Kao YH, Huang SC, et al. Toll-like receptor-4 agonist inhibits motility and invasion of hepatoblastoma HepG2 cells in vitro. Pediatr Blood Cancer 2013;60:248-53.
39. Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA 2012;109:E2110-2116.
40. Chen X, Liang H, Zhang J, et al. microRNAs are ligands of Toll-like receptors. RNA 2013;19:737-9.
41. Ochi A, Graffeo CS, Zambirinis CP, et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest 2012; 122:4118-29.
42. Ito T, Amakawa R, Fukuhara S. Roles of toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. Hum Immunol 2002;63:1120-5.
43. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65:5009-14.
44. He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007;44:2850-9.
45. Bhattacharya D, Yusuf N. Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int J Breast Cancer 2012;2012:716564.
46. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
47. Galluzzi L, Vacchelli E, Eggermont A, et al. Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716.
48. Koizumi S, Masuko K, Wakita D, et al. Extracts of Larix Leptolepis effectively augments the generation of tumor antigen-specific cytotoxic T lymphocytes via activation of dendritic cells in TLR-2 and TLR-4-dependent manner. Cell Immunol 2012;276:153-61.
49. D'Agostino D, Racioppi M, Filianoti A, et al. Therapy for non-muscle invasive bladder cancer: HP-NAP. Urologia 2012;79:142-8.
50. Lin H, Hua F, Hu ZW. Autophagic flux, supported by toll-like receptor 2 activity, defends against the carcinogenesis of hepatocellular carcinoma. Autophagy 2012;8:1859-61.
51. Lin H, Yan J, Wang Z, et al. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice. Hepatology 2013;57:171-82.
52. Estornes Y, Toscano F, Virard F, et al. dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell Death Differ 2012;19:1482-94.
53. Shatz M, Menendez D, Resnick MA. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res 2012;72:3948-57.
54. Guo Z, Chen L, Zhu Y, et al. Double-stranded RNA-induced TLR3 activation inhibits angiogenesis and triggers apoptosis of human hepatocellular carcinoma cells. Oncol Rep 2012;27:396-402.
55. Shime H, Matsumoto M, Oshiumi H, et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA 2012;109:2066-71.
56. Levitzki A. Targeting the immune system to fight cancer using chemical receptor homing vectors carrying polyinosine/cytosine (PolyIC). Front Oncol 2012;2:4.
57. Wang C, Zhuang Y, Zhang Y, et al. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Vaccine 2012;30:4790-9.
58. Drobits B, Holcmann M, Amberg N, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumorkilling effector cells. J Clin Invest 2012;122:575-85.
59. Inglefield JR, Dumitru CD, Alkan SS, et al. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res 2008;28:253-63.
60. Weigel BJ, Cooley S, DeFor T, et al. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. Am J Hematol 2012;87:953-6.
61. Hotz C, Bourquin C. Systemic cancer immunotherapy with Toll-like receptor 7 agonists: timing is everything. Oncoimmunology 2012;1: 227-8.
62. Vincent IE, Zannetti C, Lucifora J, et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PloS One 2011;6:e26315.
63. Ray A, Tian Z, Das DS, et al. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia 2014;28:1716-24.
64. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008;179:53-6.
65. Vacchelli E, Eggermont A, Sautes-Fridman C, et al. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013;2:e25238.
66. Kanzler H, Barrat FJ, Hessel EM, et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552-9.
67. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374: 301-14.
68. Burdelya LG, Brackett CM, Kojouharov B, et al. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci USA 2013;110:E1857-1866.
69. Chang YC, Madkan V, Cook-Norris R, et al. Current and potential uses of imiquimod. South Med J 2005;98:914-20.
70. Dummer R, Hauschild A, Becker JC, et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008; 14:856-64.
71. Zhang H, Liu L, Yu D, et al. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PloS One 2012;7:e38111.
72. Mason KA, Hunter NR. CpG plus radiotherapy: a review of preclinical works leading to clinical trial. Front Oncol 2012;2:101.
73. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320:226-30.
74. Jeung HC, Moon YW, Rha SY, et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol 2008;19:520-6.
75. Cerullo V, Diaconu I, Romano V, et al. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther 2012;20:2076-86.
76. Salaun B, Romero P, Lebecque S. Toll-like receptors two-edged sword: when immunity meets apoptosis. Eur J Immunol 2007;37: 3311-8.
77. Nystrom S, Antoine DJ, Lundback P, et al. TLR activation regulates damage-Associated molecular pattern isoforms released during pyroptosis. Embo J 2013;32:86-99.
78. Bortoluci KR, Medzhitov R. Control of infection by pyroptosis and autophagy: role of TLR and NLR. Cell Mol Life Sci 2010;67: 1643-51.
79. Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother 2013;62:405-10.
80. Salaun B, Coste I, Rissoan MC, et al. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176:4894-901.
81. Garaude J, Kent A, van Rooijen N, et al. Simultaneous targeting of tolland nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012;4:120ra116.
82. Zhao Y, Yang J, Shi J, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011;477: 596-600.
83. Garaude J, Blander JM. Attacking tumor cells with a dual ligand for innate immune receptors. Oncotarget 2012;3:361-2.
84. Liu L, McKeehan WL, Wang F, et al. MAP1S enhances autophagy to suppress tumorigenesis. Autophagy 2012;8:278-80.
85. Xie R, Nguyen S, McKeehan K, et al. Microtubule-Associated protein 1S (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation. J Biol Chem 2011;286:10367-77.
86. Zalckvar E, Berissi H, Mizrachy L, et al. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep 2009;10:285-92.
87. Michels J, Kepp O, Senovilla L, et al. Functions of BCL-X L at the Interface between cell death and metabolism. Int J Cell Biol 2013;2013:705294.
88. Menendez D, Shatz M, Resnick MA. Interactions between the tumor suppressor p53 and immune responses. Curr Opin Oncol 2013;25: 85-92.
89. Yao Y, Shi M, Liu S, et al. MARVELD1 modulates cell surface morphology and suppresses epithelial-mesenchymal transition in nonsmall cell lung cancer. Mol Carcinog 2015.
90. Wang ZY, Shi M, Li Y. Importin-beta1 plays a key role in the nucleocytoplasmic transportation process of MARVELD1. Mol Biol (Mosk) 2015;49:491-7.
91. Shi M, Wang S, Yao Y, et al. Biological and clinical significance of epigenetic silencing of MARVELD1 gene in lung cancer. Sci Rep 2014;4:7545.
92. Wang S, Hu J, Yao Y, et al. MARVELD1 regulates integrin beta1-mediated cell adhesion and actin organization via inhibiting its premRNA processing. Int J Biochem Cell Biol 2013;45:2679-87.
93. Yu Y, Zhang Y, Hu J, et al. MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma. Cancer Sci 2012;103:716-22.